AI
CLYM

ArchPoint Investors’s Climb Bio CLYM Stock Holding History

ArchPoint Investors’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
128,900
+7,500
+6% +$77.5K 0.36% 48
2026
Q1 		$832K Hold
121,400
– – 0.2% 54
2025
Q4 		$486K Buy
+121,400
New +$292K 0.12% 59

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ArchPoint Investors's CLYM Position: Q2 2026 in Review

ArchPoint Investors increased its Climb Bio (CLYM) stake by 6.2% in Q2 2026, buying an estimated $77.5K and bringing the position to 128,900 shares worth $1.68M. The position accounts for 0.36% of the portfolio, ranked #48.

ArchPoint Investors first reported a position in CLYM in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • ArchPoint Investors held 128,900 shares of Climb Bio worth $1.68M as of Q2 2026.
  • ArchPoint Investors bought 7,500 Climb Bio shares in Q2 2026, an estimated $77.5K.
  • Climb Bio made up 0.36% of ArchPoint Investors's portfolio in Q2 2026, its #48 holding.
  • ArchPoint Investors first reported a position in Climb Bio in Q4 2025 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on ArchPoint Investors's 13F filing for Q2 2026, filed 13 Aug 2026.